Bendell, J. C., Varghese, A. M., Hyman, D. M., Bauer, T. M., Pant, S., Callies, S., . . . Moore, K. N. (2018). A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical cancer research, 24(14), 3253. https://doi.org/10.1158/1078-0432.CCR-17-3421
Citace podle Chicago (17th ed.)Bendell, Johanna C., et al. "A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer." Clinical Cancer Research 24, no. 14 (2018): 3253. https://doi.org/10.1158/1078-0432.CCR-17-3421.
Citace podle MLA (9th ed.)Bendell, Johanna C., et al. "A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer." Clinical Cancer Research, vol. 24, no. 14, 2018, p. 3253, https://doi.org/10.1158/1078-0432.CCR-17-3421.